Aclarion, Inc. (NASDAQ:ACON – Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,810,000 shares, a growth of 47.2% from the December 15th total of 1,230,000 shares. Currently, 17.4% of the shares of the company are short sold. Based on an average daily volume of 6,370,000 shares, the days-to-cover ratio is presently 0.3 days.
Aclarion Stock Down 55.6 %
ACON stock opened at $0.04 on Thursday. The company has a 50-day simple moving average of $0.16 and a 200 day simple moving average of $0.20. Aclarion has a fifty-two week low of $0.03 and a fifty-two week high of $3.85.
Wall Street Analyst Weigh In
ACON has been the topic of a number of recent analyst reports. Ascendiant Capital Markets cut their price target on Aclarion from $1.50 to $1.30 and set a “buy” rating on the stock in a report on Wednesday, November 27th. Maxim Group reaffirmed a “hold” rating on shares of Aclarion in a research note on Friday, December 13th.
About Aclarion
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
See Also
- Five stocks we like better than Aclarion
- What is a Bond Market Holiday? How to Invest and Trade
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- 3 Fintech Stocks With Good 2021 Prospects
- How Do Stock Buybacks Affect Shareholders?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.